Merav Cohen-Israel1, Itai Berger2, Einat Y Martonovich1,3, Gil Klinger1,4, Bracha Stahl3, Nehama Linder3,4. 1. Department of Pediatrics, Schneider Children's Medical Center of Israel, Petach Tikva, Israel. 2. Pediatric Neurology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Department of Neonatology, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
AIMS: The present study evaluates the effect of antenatal lamotrigine exposure, on short- and long-term paediatric outcome. METHODS: The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014. All newborns were monitored for vital signs, congenital malformations and Finnegan score. In addition, the parents completed a questionnaire regarding their child's development and health up to the age of 12 years. RESULTS: No major malformations were found in the newborns. None of the newborns had significant withdrawal symptoms by Finnegan score. The children were followed-up to the age of 12 years (56.6% were 6-12 years at the time of evaluation). There were no significant findings in the incidence of neurodevelopmental disorders. CONCLUSIONS: According to our experience, lamotrigine is generally safe for pregnancy use, associated with minimal short-term complications with no long-term effects on the outcome.
AIMS: The present study evaluates the effect of antenatal lamotrigine exposure, on short- and long-term paediatric outcome. METHODS: The study included the children of 83 epilepticwomen treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014. All newborns were monitored for vital signs, congenital malformations and Finnegan score. In addition, the parents completed a questionnaire regarding their child's development and health up to the age of 12 years. RESULTS: No major malformations were found in the newborns. None of the newborns had significant withdrawal symptoms by Finnegan score. The children were followed-up to the age of 12 years (56.6% were 6-12 years at the time of evaluation). There were no significant findings in the incidence of neurodevelopmental disorders. CONCLUSIONS: According to our experience, lamotrigine is generally safe for pregnancy use, associated with minimal short-term complications with no long-term effects on the outcome.
Authors: Gus A Baker; Rebecca L Bromley; Maria Briggs; Christopher P Cheyne; Morris J Cohen; Marta García-Fiñana; Alison Gummery; Rachel Kneen; David W Loring; George Mawer; Kimford J Meador; Rebekah Shallcross; Jill Clayton-Smith Journal: Neurology Date: 2014-12-24 Impact factor: 9.910
Authors: Rebecca Louise Bromley; George E Mawer; Maria Briggs; Christopher Cheyne; Jill Clayton-Smith; Marta García-Fiñana; Rachel Kneen; Sam B Lucas; Rebekah Shallcross; Gus A Baker Journal: J Neurol Neurosurg Psychiatry Date: 2013-01-31 Impact factor: 10.154
Authors: Jana E Jones; Miya R Asato; Mesha-Gay Brown; Julia L Doss; Elizabeth A Felton; Jennifer A Kearney; Delia Talos; Penny A Dacks; Vicky Whittemore; Annapurna Poduri Journal: Epilepsy Curr Date: 2020-01-23 Impact factor: 7.500